Citi raised the firm’s price target on ArriVent Biopharma (AVBP) to $45 from $33 and keeps a Buy rating on the shares. The firm expects the company to announce positive data from the Phase 3 FURVENT trial in first-line EGFR Exon 20 insertion non-small cell lung cancer in Q2 or Q3. Citi believes the stock can rise 50% on its base case readout and 100% on its bull case.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVBP:
- ArriVent Biopharma price target raised to $45 from $37 at B. Riley
- ArriVent Highlights Next-Generation Oncology Data at AACR 2026
- ArriVent Biopharma assumed with a Buy at BTIG
- ArriVent: Undervalued EGFR Franchise With Pivotal Firmonertinib Upside and Emerging ADC Optionality Driving Buy Rating and $42 Target
- ArriVent Biopharma price target raised to $50 from $44 at Oppenheimer